Login to Your Account

Pharma: Clinic Roundup

Thursday, March 8, 2012
• Forest Laboratories Inc., of New York, and Pierre Fabre Medicament, of Castres, France, reported top-line results in a Phase III trial showing that levomilnacipran significantly reduced depression symptoms in patients with major depressive disorder compared to placebo, as early as week one and at each subsequent visit, as measured by the Montgomery-Asberg Depression Rating Scale-Clinician Rated.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription